Source: Eur Respir J, 58 (1) 2100342; 10.1183/13993003.00342-2021
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Robert P. Young, Raewyn J. Scott. Statins as adjunct therapy in COPD: is it time to target innate immunity and cardiovascular risk?. Eur Respir J, 58 (1) 2100342; 10.1183/13993003.00342-2021

Member's Comments

No comment yet.

Related content which might interest you: Biomarkers for activation of the inflammatory and immune systems in the risk of mortality in critically-ill COVID-19 patients Source: Virtual Congress 2021 – Respiratory failure in COVID19 and beyond Year: 2021 30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator? Source: ERJ Open Res, 4 (4) 00030-2018; 10.1183/23120541.00030-2018 Year: 2018 Assessment of innate immunity mediators in the lung of COPD patients: relation with disease manifestations Source: Virtual Congress 2020 – Host-microbe interactions and their influence on lung disease onset and severity Year: 2020 Improving the innate immune response in respiratory infections: the use of repurposed drugs Source: Virtual Congress 2020 – Antibiotic resistance: the way forward Year: 2020 Primary prevention of asthma: from risk and protective factors to targeted strategies for prevention Source: Virtual Congress 2020 – Reducing the burden of asthma Year: 2020 Emerging concern of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017 Known and emerging risk factors for asthma development: is prevention possible? Source: International Congress 2015 – Asthma: emerging risk factors and current management of the patient Year: 2015 Evaluation of tuberculosis risk in patients submitted to chronic immunosuppressive therapy for osteoarticular immune disease Source: Eur Respir J 2006; 28: Suppl. 50, 131s Year: 2006 Immunoproteasome function as a potential biomarker for asthma severity and response to therapy Source: Virtual Congress 2021 – Emerging new mechanisms of chronic lung disease Year: 2021 Is inflammation a potential therapeutic target in chronic thromboembolic pulmonary hypertension? Source: Eur Respir J 2014; 44: 842-845 Year: 2014 Management of patients with asthma or COPD and cardiovascular disease: risks versus benefits Source: Eur Respir Monogr 2020; 88: 66-81 Year: 2020 Do cardiovascular drugs reduce exacerbations rates in primary care patients with COPD? Source: Eur Respir J 2007; 30: Suppl. 51, 126s Year: 2007 Macrolide therapy for pneumonia: balancing benefits with cardiovascular risks Source: International Congress 2014 – ERS/JAMA lunchtime session: 2014 highlights Year: 2014 The risk of cardiovascular disease associated with asthma may be mediated by short-acting β2-agonists Source: Annual Congress 2008 - Epidemiology of asthma and allergy Year: 2008 Cardiovascular comorbidities in hospitalised COPD patients: a determinant of future risk? Source: Eur Respir J 2015; 46: 846-849 Year: 2015 Is there a strong relationship between COPD and cardiovascular diseases? Source: Annual Congress 2013 –The latest insights in respiratory muscles, neuromuscular disease and comorbidities Year: 2013 Macrolides targeting multiple immune pathways in asthma and COPD Source: Virtual Congress 2021 – Pharmacology of lung immune responses: which pathways to target! Year: 2021